Expert Review of Neurotherapeutics最新文献

Recent therapeutic advances in the treatment and management of amyotrophic lateral sclerosis: the era of regenerative medicine. 肌萎缩性侧索硬化症治疗和管理的最新进展：再生医学的时代。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-21 DOI: 10.1080/14737175.2025.2508781

Fabiola De Marchi, Ivan Lombardi, Alessandro Bombaci, Luca Diamanti, Marco Olivero, Elisa Perciballi, Danilo Tornabene, Edvige Vulcano, Daniela Ferrari, Letizia Mazzini

{"title":"Recent therapeutic advances in the treatment and management of amyotrophic lateral sclerosis: the era of regenerative medicine.","authors":"Fabiola De Marchi, Ivan Lombardi, Alessandro Bombaci, Luca Diamanti, Marco Olivero, Elisa Perciballi, Danilo Tornabene, Edvige Vulcano, Daniela Ferrari, Letizia Mazzini","doi":"10.1080/14737175.2025.2508781","DOIUrl":"10.1080/14737175.2025.2508781","url":null,"abstract":"Introduction: Despite decades of research, effective disease-modifying treatments for Amyotrophic Lateral Sclerosis (ALS) remain scarce. The emergence of regenerative medicine presents a new frontier for ALS treatment.Areas covered: This review is based on a comprehensive literature search using PubMed, Scopus and clinical trials databases on the recent therapeutic advancements in ALS, giving focus to regenerative medicine. The article includes coverage of stem cell-based therapies, including mesenchymal, neural and induced pluripotent stem cells; all of which may offer potential neuroprotective and immunomodulatory effects. Gene therapy, particularly antisense oligonucleotides targeting ALS-related mutations, has gained traction, with tofersen becoming the first FDA-approved genetic therapy for ALS. The article also covers emerging approaches such as extracellular vesicles, immune-modulating therapies, and bioengineering techniques, including CRISPR-based gene editing and cellular reprogramming, that hold promise for altering disease progression.Expert opinion: While regenerative medicine provides hope for ALS patients, significant challenges remain. Biomarkers will play a crucial role in guiding personalized treatment strategies, ensuring targeted interventions. Future research should prioritize optimizing combinatory approaches, integrating different therapy strategies to maximize patient outcomes. Although regenerative medicine is still in its early clinical stages, its integration into ALS treatment paradigms could redefine disease management and alter its natural course.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-17"},"PeriodicalIF":3.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could self-reporting sleep duration become an important tool in the prediction of dementia? 自我报告睡眠时间能否成为预测痴呆的重要工具？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-17 DOI: 10.1080/14737175.2025.2506459

Marina Šagud, Maja Bajs Janović, Suzana Uzun, Biljana Kosanović Rajačić, Oliver Kozumplik, Nela Pivac

{"title":"Could self-reporting sleep duration become an important tool in the prediction of dementia?","authors":"Marina Šagud, Maja Bajs Janović, Suzana Uzun, Biljana Kosanović Rajačić, Oliver Kozumplik, Nela Pivac","doi":"10.1080/14737175.2025.2506459","DOIUrl":"https://doi.org/10.1080/14737175.2025.2506459","url":null,"abstract":"Introduction: Optimal sleep duration is increasingly recognized as an important determinant of overall health, including cognitive functioning. Studies often report a U- or J-shaped relationship between sleep duration and incident dementia or cognitive deterioration, whereas long sleep, the extremes of sleep duration, and the transition to long sleep were particularly detrimental. In preclinical studies, partial or complete sleep deprivation produced inflammation, oxidative stress, as well as increased tau hyperphosphorylation and amyloid-β burden. In humans, although the findings are less pronounced, they still highlight that transitioning to an excessive sleep duration is associated with neurodegeneration. Moreover, the association between sleep duration and dementia is complex and modified by genetic, psychosocial and lifestyle factors, along with psychiatric and somatic comorbidities.Areas covered: The purpose of this perspective is to summarize the current knowledge on the association between sleep duration and dementia. It is based on a literature search for meta-analyses of prospective studies with sleep duration as an exposure and dementia as an outcome.Expert opinion: Sleep duration is a modifiable risk factor for dementia while long sleep may be an early sign of neurodegeneration. Therefore, self-reported sleep duration is an easy-to-use tool for detecting individuals who may be at risk for cognitive deterioration.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-15"},"PeriodicalIF":3.4,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the evaluation of treatment switching criteria in multiple sclerosis. 多发性硬化症治疗转换标准评估的最新进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-15 DOI: 10.1080/14737175.2025.2506462

Kevin Bigaut, Judicaelle Didierjean, Jerome de Seze

{"title":"An update on the evaluation of treatment switching criteria in multiple sclerosis.","authors":"Kevin Bigaut, Judicaelle Didierjean, Jerome de Seze","doi":"10.1080/14737175.2025.2506462","DOIUrl":"10.1080/14737175.2025.2506462","url":null,"abstract":"Introduction: Multiple sclerosis (MS) is a complex disorder driven by both inflammatory and neurodegenerative processes. While disease-modifying therapies (DMTs) have significantly improved prognosis, robust treatment switching criteria remain essential to balance efficacy and safety over the disease course.Areas covered: This review examines historical and current criteria for escalating DMTs from moderate- to high-efficacy therapies (HET). The authors summarize emerging clinical, imaging, and biological markers that inform decision-making and explore strategies for de-escalation, including DMT discontinuation and innovative approaches such as exit and bridge therapies.Expert opinion: Recent advances in MS management emphasize earlier initiation of HET and more stringent switching criteria. Although innovative monitoring tools - including clinical evaluations, imaging, biological markers, and patient-reported outcomes (PROs) - enhance disease assessment, they require further validation, standardization, and broader accessibility. Similarly, de-escalation criteria need additional research to optimize patient selection.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-18"},"PeriodicalIF":3.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Insights and Strategies to Managing Depression Subtypes Associated with Tobacco dependence: A Response to the Letter to the Editor. 管理与烟草依赖相关的抑郁症亚型的临床见解和策略：对致编辑的信的回应。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-14 DOI: 10.1080/14737175.2025.2506463

Stefania Chiappini, Gaia Sampogna, Antonio Ventriglio, Giulia Menculini, Valerio Ricci, Mauro Pettorruso, Umberto Volpe, Giovanni Martinotti

引用次数: 0

Tobacco use disorder and depression: emerging strategies and recommendations. 烟草使用障碍和抑郁症：新出现的战略和建议。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-14 DOI: 10.1080/14737175.2025.2506460

Raul Felipe Palma-Alvarez

引用次数: 0

Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues. 意识障碍早期和长期恢复的药物治疗：目前的知识和有希望的途径。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-07 DOI: 10.1080/14737175.2025.2500757

Rosalie Girard Pepin, Fatemeh Seyfzadeh, David Williamson, Olivia Gosseries, Catherine Duclos

{"title":"Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues.","authors":"Rosalie Girard Pepin, Fatemeh Seyfzadeh, David Williamson, Olivia Gosseries, Catherine Duclos","doi":"10.1080/14737175.2025.2500757","DOIUrl":"https://doi.org/10.1080/14737175.2025.2500757","url":null,"abstract":"Introduction: Disorders of consciousness (DoC) are characterized by impaired arousal and/or awareness, ranging from coma to unresponsive wakefulness syndrome, minimally conscious state, and cognitive motor dissociation. Pharmacological treatment options remain limited, complicated by the heterogeneity of etiologies, such as traumatic brain injury, stroke, and infections. The lack of rigorous clinical trials has led to off-label use of treatments, often without clear mechanistic understanding, posing challenges for effective patient care.Areas covered: In this perspective, the authors report on key studies concerning the effectiveness of pharmacological interventions, including dopaminergic and GABAergic agents, antidepressants, statins, and anticonvulsants, in promoting recovery of consciousness in DoC.Expert opinion: Robust longitudinal clinical trials are needed, with priority given to early subacute phase intervention. Outcomes should be better defined, considering immediate responses to medication while also increasing the emphasis on long-term quality of life. Unified functional and mechanistic frameworks are needed to guide research and foster collaboration. Furthermore, a shift toward personalized medicine would benefit this heterogeneous population. Moving forward, assessing the efficacy of more unconventional or 'paradoxical' pharmacological options in treatment plans will be essential. The authors also expect an increased use of AI tools to identify factors that best predict treatment responses.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-21"},"PeriodicalIF":3.4,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The latest therapeutic advances with spontaneous intracerebral hemorrhage. 自发性脑出血的最新治疗进展。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-06 DOI: 10.1080/14737175.2025.2502048

Michael Griffin, Chun Shing Kwok, Adnan I Qureshi, Gregory Y H Lip

{"title":"The latest therapeutic advances with spontaneous intracerebral hemorrhage.","authors":"Michael Griffin, Chun Shing Kwok, Adnan I Qureshi, Gregory Y H Lip","doi":"10.1080/14737175.2025.2502048","DOIUrl":"10.1080/14737175.2025.2502048","url":null,"abstract":"Introduction: Intracerebral hemorrhage (ICH) accounts for 10% of strokes; however, compared with ischemic stroke, progress leading to novel treatments and improved patient outcomes has been lacking. Recently, there have been several promising developments and renewed research interest within the field. Positive results from randomized controlled trials have now been reported in multiple domains of care for patients with ICH. Anticoagulation-associated ICH is increasingly frequent, and clinicians deciding on reversal and timing of re-initiation of oral anticoagulation now have more therapeutic agents available and evidence to guide them. Minimally invasive techniques are also added to the neurosurgical arsenal, leading to improvements in functional outcomes. Acute treatment at presentation is best served by bundled care approaches, which ensure goal-directed management of blood pressure, glucose and temperature.Areas covered: This narrative review summarizes the recent developments in this area, as well as the current recommendations of key international guidelines. Literature search was carried out using PubMed database with priority given to publications since 2020.Expert opinion: There is renewed optimism for innovation in ICH. The standard of care for this condition now leads to improvements in mortality and long-term functional ability. Efforts to improve the patient selection and surgical techniques for operative management are ongoing.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of botulinum neurotoxin-A in the treatment of neuropsychiatric symptoms in patients with Parkinson's disease: an open-label randomized controlled study. 肉毒杆菌神经毒素a治疗帕金森病患者神经精神症状的疗效：一项开放标签随机对照研究

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-06 DOI: 10.1080/14737175.2025.2500753

Xiaofeng Zhu, Xiu Yang, Ming Wei, Huayan Wang, Jun Shen, Qiu Han

{"title":"Efficacy of botulinum neurotoxin-A in the treatment of neuropsychiatric symptoms in patients with Parkinson's disease: an open-label randomized controlled study.","authors":"Xiaofeng Zhu, Xiu Yang, Ming Wei, Huayan Wang, Jun Shen, Qiu Han","doi":"10.1080/14737175.2025.2500753","DOIUrl":"https://doi.org/10.1080/14737175.2025.2500753","url":null,"abstract":"Objectives: Parkinson's disease (PD) often presents with neuropsychiatric symptoms that worsen quality of life. The aim of this study was to evaluate the effectiveness of Botulinum neurotoxin-A (BTX-A) in managing neuropsychiatric manifestations in PD patients.Methods: Neuropsychiatric status was assessed in 185 PD patients using the Cornell Medical Index (CMI). Ninety-four patients exhibiting neuropsychiatric symptoms were randomly assigned to two groups: BTX-A (n=47, local injections) and citalopram (n=47, 10-40 mg/day). Outcomes were compared at baseline and 8 weeks post-treatment.Results: The authors findings revealed a significant reduction in somatization, tension, anxiety, depression, sensitivity, and overall scores in the BTX-A group at the eight-week follow-up (p < 0.05 for all). Notably, patients in the BTX-A group exhibited similar levels of somatization, depression, anxiety, maladjustment, sensitivity, anger, and overall scores compared to the citalopram group (p > 0.05 for all). Both groups reported comparable percentages of improvement in neuropsychiatric symptoms (75.6% vs. 82.6%, p = 0.57).Conclusions: This study demonstrates the potential of BTX-A in alleviating tension, anxiety, depression, sensitivity, and other neuropsychiatric symptoms in PD patients. Importantly, BTX-A's efficacy was comparable to that of citalopram, suggesting its potential as a viable therapeutic option for managing neuropsychiatric manifestations in PD.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead. 抗淀粉样蛋白单克隆抗体治疗阿尔茨海默病的不确定性：未来的挑战。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-05 DOI: 10.1080/14737175.2025.2500752

Madia Lozupone, Vittorio Dibello, Emanuela Resta, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Anita Mollica, Giuseppe Berardino, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Francesco Panza

{"title":"Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead.","authors":"Madia Lozupone, Vittorio Dibello, Emanuela Resta, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Anita Mollica, Giuseppe Berardino, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Francesco Panza","doi":"10.1080/14737175.2025.2500752","DOIUrl":"https://doi.org/10.1080/14737175.2025.2500752","url":null,"abstract":"Introduction: Alzheimer's disease (AD), the leading cause of dementia, poses a significant burden on patients, caregivers, and healthcare systems worldwide. After two decades of extensive efforts, we are still without significantly effective disease-modifying drugs for AD. Although brain amyloid-β (Aβ) accumulation may predict cognitive decline, several drug candidates, including anti-Aβ monoclonal antibodies, have been developed and tested to reduce Aβ plaque burden effective, but without significant clinical success.Areas covered: The following review presents and discusses anti-Aβ monoclonal antibody therapeutics used to treat AD. The article considers both current approaches and alternatives. This article is multiple database searches (MEDLINE, EMBASE, Scopus, Ovid and Google Scholar) on all the available literature up to 1 February 2025.Expert opinion: Randomized clinical trials (RCTs) of anti-Aβ drugs in AD have not fully validated the Aβ cascade hypothesis. Nevertheless, eight anti-Aβ monoclonal antibodies have, thus far, made it to Phase III RCTs. Moving forward, the use of the Apolipoprotein E genotype and tau protein as alternative biomarkers can assist clinicians in providing patients with even more individualized and efficacious anti-Aβ monoclonal antibodies dosing regimens and reduce the risk of serious amyloid-related imaging abnormalities.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder. 英国医用大麻登记处：创伤后应激障碍患者的最新临床结果分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2025-05-01 Epub Date: 2025-04-18 DOI: 10.1080/14737175.2025.2490539

Aritra Datta, Simon Erridge, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren

{"title":"UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder.","authors":"Aritra Datta, Simon Erridge, John Warner-Levy, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren","doi":"10.1080/14737175.2025.2490539","DOIUrl":"https://doi.org/10.1080/14737175.2025.2490539","url":null,"abstract":"Background: Cannabis-based medicinal products (CBMPs) are a potential treatment for post-traumatic stress disorder (PTSD), but their long-term efficacy and safety need further investigation. This study assessed the changes in health-related quality of life (HRQoL) and adverse events in PTSD patients prescribed CBMPs.Research design and methods: This observational cohort study included PTSD patients enrolled on the UK Medical Cannabis Registry for 18 months or longer. Changes in PTSD-specific symptoms (IES-R), anxiety (GAD-7), sleep quality (SQS), and general HRQoL (EQ-5D-5 L) were assessed at 1, 3, 6, 12, and 18 months.Results: In 269 patients, significant improvements in PTSD symptoms, anxiety, sleep quality, and HRQoL were observed at all follow-up points (p < 0.001). On multivariate logistic regression, male gender (OR = 0.51; 95% CI:0.28-0.94; p = 0.034) was associated with a reduced chance of reporting improvements in IES-R. Adverse events were reported by 70 (26.02%) patients, with insomnia (n = 42, 15.61%) and fatigue (n = 40, 14.87%) being the most common.Conclusions: CBMPs were associated with improvements in PTSD symptoms, anxiety, sleep, and HRQoL at up to 18 months. Although the study's observational nature limits causal conclusions, these findings support further assessment of medical cannabis.Trial registration: This is an observational study and is not registered as a clinical trial.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"25 5","pages":"599-607"},"PeriodicalIF":3.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0